Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Oxford-based immuno-oncology play Adaptimmune has been obliged by the FDA to alter the trial design of a Phase I/II study in patients with MRCLS. A partial clinical hold was lifted now.
Belgian and German researchers have presented a new imaging tool that can track immune cells invading the brain in the initial stages of multiple sclerosis (MS).
Despite declining numbers of IPOs, financing rounds and licensing deals, the European biotech sector presented itself optimistic and self-confident during BIO-Europe in Cologne. The three-days partnering event again see a record number of participants.
After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest of lung cancer patients.
While DG Research has delayed its update on the European Bioeconomy Strategy and Action Plan until next June, the Central and Eastern Bioregions presented a blueprint that proposes key actions aimed at integrating the goals of the European Commissions circular economy and the bioeconomy strategies.
A new analysis comparing the amount of funding invested into stem cell research clearly demonstrates declining investment in Germany. In contrast, the US, the UK, Sweden and Japan have increased their investments into the future field.
Investors are once again flocking to back biotechs in Europe. Belgian Life Sciences fund Fund+ has raised €125m – a quarter more than initially anticipated.
Part microbe, part machine: cyborg bacteria developed at ETH Zurich could revolutionise the biotechnological production of molecules. The bacteria have been engineered to respond to light signals.